Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | P2RX7 | Q99572 | 12/20 | 0.33 |
| ▸ | S100A4 | P26447 | 1/20 | 0.31 |
| ▸ | CDC25B | P30305 | 1/20 | 0.31 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2691280 | 0.82 | TRPV1 (0.41) | TRPV1MEN1CYP2C9KMT2AP2RX7 | |
| SCHEMBL2690334 | 0.82 | NOS3 (0.36) | TRPV1MEN1CYP2C9KMT2AHSD11B1 | |
| SCHEMBL2688435 | 0.81 | TRPV1 (0.34) | TRPV1MEN1CYP2C9KMT2AP2RX7 | |
| SCHEMBL2688285 | 0.80 | TRPV1 (0.39) | TRPV1MEN1CYP2C9KMT2AP2RX7 | |
| SCHEMBL12178980 | 0.79 | TRPV1 (0.44) | TRPV1MEN1CYP2C9KMT2A | |
| SCHEMBL2692040 | 0.79 | TRPV1 (0.39) | TRPV1P2RX7 | |
| SCHEMBL22423707 | 0.78 | PDE4A (0.33) | TRPV1MEN1CYP2C9KMT2A | |
| SCHEMBL14950751 | 0.77 | TRPV1 (0.52) | TRPV1MEN1KMT2AP2RX7HSD11B1 | |
| Hydrochloric Acid SCHEMBL14936197 | 0.77 | TRPV1 (0.44) | TRPV1MEN1CYP2C9KMT2A | |
| SCHEMBL2689654 | 0.77 | ALOX5 (0.37) | TRPV1MEN1CYP2C9KMT2AHSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8338603-B2 | TRPV1 antagonists | ABBVIE INC. (US) | 2012-12-25 | — | — | US | disclosed |
| US-20120108642-A1 | TRPV1 ANTAGONISTS | ABBVIE INC. | 2012-05-03 | — | — | US | disclosed |
| US-8084616-B2 | TRPV1 antagonists | ABBOTT LABORATORIES (US) | 2011-12-27 | — | — | US | disclosed |
| EP-2215061-A2 | TRPV1 ANTAGONISTS | Abbott Laboratories (US) | 2010-08-11 | — | — | EP | disclosed |
| US-20090124671-A1 | TRPV1 ANTAGONISTS | ABBOTT LABORATORIES (US) | 2009-05-14 | — | — | US | disclosed |
| WO-2009055629-A2 | CYCLOHEXENEAMIDE DERIVATIVES AND THEIR USE AS TRPV1 ANTAGONIST | ABBOTT LABORATORIES (US) | 2009-04-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120108642-A1 | TRPV1 ANTAGONISTS | TRPV1, TRPV5, TRPV3 | TRPV1 1/4885MEN1 3210/4885CYP2C9 2980/4885 |
| US-20090124671-A1 | TRPV1 ANTAGONISTS | TRPV1, TRPV5, TRPV3 | TRPV1 1/4885MEN1 3210/4885CYP2C9 2980/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.